Medical Regulations Gate - MRG

Welcome to Medical Regulations Gate (MRG). We have brought together a team of highly qualified experts that are associated with a deep and solid level of professionalism to ensure the compliance of your medical devices with Saudi Arabia's medical regulations in order to be placed in the Saudi market.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MEDTECH

TAVOTEK BIOTHERAPEUTICS ANNOUNCES COMPLETION OF ROUND B FINANCING WITH $35 MILLION

Tavotek | November 19, 2021

news image

Tavotek Biotherapeutics, a fast-growing biotech company, announces it has raised $35M in Round B financing. CS Capital, a leading private equity fund manager in China, led this finance round followed by Fontus Capital. This round of financing will be used to accelerate the Phase 1 clinical development of several antibody drugs to start in early 2022. The upcoming antibody drugs were developed by the company based on its TavoPrecise antibody platform for various immune-related disorders. In addit...

Read More

MEDICAL

SOSEI HEPTARES' COVID-19 PROGRAM IDENTIFIES POTENT BROAD SPECTRUM ANTI-VIRAL SMALL MOLECULES FOR FURTHER DEVELOPMENT

Sosei Heptares | November 21, 2020

news image

Sosei Group Corporation ("the Company") (TSE: 4565) announces a progress update for its R&D program focused on the design and development of novel drugs targeting the SARS-CoV-2 coronavirus and to treat COVID-19.The program was initiated in April 2020. To date, the Company has applied its world-leading structure-based drug design (SBDD) capabilities and cutting-edge technologies to precision-design new inhibitors of the SARS-CoV-2 Mpro protease, which plays a crucial role in ...

Read More

INDUSTRIAL IMPACT

OMEGA THERAPEUTICS ANNOUNCES STRATEGIC RESEARCH COLLABORATION WITH STANFORD UNIVERSITY SCHOOL OF MEDICINE

Omega Therapeutics, Inc | October 14, 2021

news image

Omega Therapeutics, Inc. ("Omega"), a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programing™ platform, today announced a strategic research collaboration with researchers at the Stanford University School of Medicine to explore the therapeutic potential of Omega Epigenomic Controllers (OECs) to control ocular disease genes associated with inflamma...

Read More

INDUSTRIAL IMPACT

OMASS THERAPEUTICS TO PRESENT AT UPCOMING CONFERENCESOMASS THERAPEUTICS TO PRESENT AT UPCOMING CONFERENCES

OMass Therapeutics | February 21, 2022

news image

OMass Therapeutics a biotechnology company identifying medicines against highly validated target ecosystems, is pleased to confirm that it will be presenting at a number of upcoming banking, business and scientific conferences, as detailed below. “As we develop our unique drug discovery platform, OdyssION™, and progress our pipeline of small molecule therapeutics in rare diseases and immunological conditions, targeting solute carriers, complex-bou...

Read More
news image

MEDTECH

TAVOTEK BIOTHERAPEUTICS ANNOUNCES COMPLETION OF ROUND B FINANCING WITH $35 MILLION

Tavotek | November 19, 2021

Tavotek Biotherapeutics, a fast-growing biotech company, announces it has raised $35M in Round B financing. CS Capital, a leading private equity fund manager in China, led this finance round followed by Fontus Capital. This round of financing will be used to accelerate the Phase 1 clinical development of several antibody drugs to start in early 2022. The upcoming antibody drugs were developed by the company based on its TavoPrecise antibody platform for various immune-related disorders. In addit...

Read More
news image

MEDICAL

SOSEI HEPTARES' COVID-19 PROGRAM IDENTIFIES POTENT BROAD SPECTRUM ANTI-VIRAL SMALL MOLECULES FOR FURTHER DEVELOPMENT

Sosei Heptares | November 21, 2020

Sosei Group Corporation ("the Company") (TSE: 4565) announces a progress update for its R&D program focused on the design and development of novel drugs targeting the SARS-CoV-2 coronavirus and to treat COVID-19.The program was initiated in April 2020. To date, the Company has applied its world-leading structure-based drug design (SBDD) capabilities and cutting-edge technologies to precision-design new inhibitors of the SARS-CoV-2 Mpro protease, which plays a crucial role in ...

Read More
news image

INDUSTRIAL IMPACT

OMEGA THERAPEUTICS ANNOUNCES STRATEGIC RESEARCH COLLABORATION WITH STANFORD UNIVERSITY SCHOOL OF MEDICINE

Omega Therapeutics, Inc | October 14, 2021

Omega Therapeutics, Inc. ("Omega"), a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programing™ platform, today announced a strategic research collaboration with researchers at the Stanford University School of Medicine to explore the therapeutic potential of Omega Epigenomic Controllers (OECs) to control ocular disease genes associated with inflamma...

Read More
news image

INDUSTRIAL IMPACT

OMASS THERAPEUTICS TO PRESENT AT UPCOMING CONFERENCESOMASS THERAPEUTICS TO PRESENT AT UPCOMING CONFERENCES

OMass Therapeutics | February 21, 2022

OMass Therapeutics a biotechnology company identifying medicines against highly validated target ecosystems, is pleased to confirm that it will be presenting at a number of upcoming banking, business and scientific conferences, as detailed below. “As we develop our unique drug discovery platform, OdyssION™, and progress our pipeline of small molecule therapeutics in rare diseases and immunological conditions, targeting solute carriers, complex-bou...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us